3M India Announces 506 Special Dividend and Reports 202 Profit Surge for Q4 FY26 Zscaler Stock Drops as Weak Outlook and Sales Restructuring Concern Investors Oura Health Files Confidentially for IPO as Smart Wearables Market Gains Momentum PutinXi Talks Revive Stalled Russian Gas Pipeline Amid Iran War Energy Disruptions BofA Advises Ignoring NearTerm Noise Around NVIDIA NVDA Fed Chair Powell Vows Not to Be a Shadow Chair as Potential Clash with Warsh Looms HLNE Q1 2026 Earnings EPS Surpasses Estimates as Hamilton Lane Navigates Private Markets Mamas Creations Inc MAMA Q1 2026 Earnings EPS Surpasses Estimates by 279 Amid Revenue and Guidance Gaps PHVS Q1 2026 Earnings NarrowerThanExpected Loss as Biotech Advances HAE Pipeline FTI Consulting FCN Q1 2026 Earnings EPS Misses Estimates Despite Modest Stock Uptick Jefferson Capital Inc JCAP Q1 2026 Earnings EPS Surpasses Estimates by 448 Amid Slight Stock Decline Solid Biosciences Q1 2026 Earnings WiderthanExpected Loss as PreRevenue Biotech Advances Pipeline TPG RE Finance Trust TRTX Holds Steady Near Support as Commercial Real Estate Sentiment Shifts Oxford Lane Capital Notes Edge Lower Remain Within Defined Range OXLCG Lightwave Logic Inc LWLG Declines Over 5 as Shares Test Key Support Levels Starbucks SBUX Slips 164 as Coffee Giant Tests Support Levels ARM Holdings Surges 48 as Semiconductor Demand Drives Momentum Navitas Stock Surges 37 as Market Awaits Strategic Business Updates VZ Q1 2026 Earnings EPS Beat on Strong Wireless Execution Civista Bancshares CIVB Holds Steady Near Support After Minor Decline NTLA Intellia Therapeutics tops Q4 2025 EPS estimates posts 169 percent yearoveryear revenue growth as shares edge slightly lower Miller Industries MLR Stock Trendline Break Bullish Sentiment 20260420 BranchOut BOF Stock Reversal 118 20260422 XWIN XMAX investors overlook Q4 loss sending shares up 114 on strategic outlook Is it too late to buy Alico ALCO stock Q1 2026 Below Expectations Gilead Sciences GILD Partner Tempus AI TEM Secures TD Cowen Buy Upgrade Amid AI Drug Development Traction BCSF Bain SpecFin edges up modestly despite posting a narrow Q4 2025 EPS miss versus analyst expectations